From stabilization to silencing in transthyretin amyloid cardiomyopathy: why sequencing should be treat-to-trajectory, not 'one-and-done'.

Abstract excerpt

Transthyretin amyloid cardiomyopathy (ATTR-CM) is now a treatable cause of heart failure, but the rapid expansion of disease-modifying therapies has introduced a practical challenge: how to choose and sequence treatments in routine care. Transthyretin (TTR) stabilizers reduce tetramer dissociation, whereas silencers reduce hepatic TTR production. Although recent randomized trials have strengthened the evidence...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Amyloid Neuropathies, Familial
• Share to Cardiomyopathies